Page 92 - 《中国药房》2024年3期

[ 5 ] KHORANA A A，KUDERER N M，CULAKOVA E，et al. PETITTO G，et al. Development of a clinical prediction
Development and validation of a predictive model for tool for cancer-associated venous thromboembolism
chemotherapy-associated thrombosis[J]. Blood，2008，111 （CAT）：the MD Anderson Cancer Center CAT model[J].
（10）：4902-4907. Support Care Cancer，2020，28（8）：3755-3761.
[ 6 ] AY C，DUNKLER D，MAROSI C，et al. Prediction of ve‐ [15] LI A，WU Q，LUO S H，et al. Derivation and validation of
nous thromboembolism in cancer patients[J]. Blood， a risk assessment model for immunomodulatory drug-
2010，116（24）：5377-5382. associated thrombosis among patients with multiple mye-
[ 7 ] VERSO M，AGNELLI G，BARNI S，et al. A modified loma[J]. J Natl Compr Canc Netw，2019，17（7）：840-847.
Khorana risk assessment score for venous thromboembo‐ [16] SANFILIPPO K M，LUO S H，WANG T F，et al. Predic-
lism in cancer patients receiving chemotherapy：the Pro‐ ting venous thromboembolism in multiple myeloma：
techt score[J]. Intern Emerg Med，2012，7（3）：291-292. development and validation of the IMPEDE VTE score[J].
[ 8 ] ANGELINI D E，GREENE M T，WIETZKE J N，et al. A Am J Hematol，2019，94（11）：1176-1184.
novel risk assessment model to predict venous throm- [17] LI Y P，SHEN L，DING J R，et al. Derivation and valida‐
boembolism （VTE） in cancer inpatients：the canclot score tion of A nomogram model for pulmonary thromboembo‐
[J]. Blood，2016，128（22）：1181. lism in patients undergoing lung cancer surgery[J]. Transl
[ 9 ] ANTIC D，MILIC N，NIKOLOVSKI S，et al. Develop‐ Lung Cancer Res，2021，10（4）：1829-1840.
ment and validation of multivariable predictive model for [18] BASTOS-OREIRO M，ORTIZ J，PRADILLO V，et al. In‐
thromboembolic events in lymphoma patients[J]. Am J corporating genetic and clinical data into the prediction of
Hematol，2016，91（10）：1014-1019. thromboembolism risk in patients with lymphoma[J]. Can‐
[10] CELLA C A，DI MINNO G，CARLOMAGNO C，et al. cer Med，2021，10（21）：7585-7592.
Preventing venous thromboembolism in ambulatory can‐ [19] HUANG W，ANDERSON F A，SPENCER F A，et al.
cer patients：the ONKOTEV study[J]. Oncologist，2017， Risk-assessment models for predicting venous thrombo‐
22（5）：601-608. embolism among hospitalized non-surgical patients：a sys‐
[11] GEROTZIAFAS G T，TAHER A，ABDEL-RAZEQ H，et tematic review[J]. J Thromb Thrombolysis，2013，35（1）：
al. A predictive score for thrombosis associated with 67-80.
breast，colorectal，lung，or ovarian cancer：the prospective [20] 李云鹂，万艳平. 恶性肿瘤相关静脉血栓栓塞症风险评
COMPASS-cancer-associated thrombosis study[J]. On‐ 估工具研究进展[J]. 中华现代护理杂志，2020，26（22）：
cologist，2017，22（10）：1222-1231. 3104-3108.
[12] MUÑOZ MARTÍN A J，ORTEGA I，FONT C，et al. Multi‐ LI Y L，WAN Y P. Research progress on risk assessment
variable clinical-genetic risk model for predicting venous tools for malignant tumor-associated venous thromboem‐
thromboembolic events in patients with cancer[J]. Br J bolism[J]. Chin J Mod Nurs，2020，26（22）：3104-3108.
Cancer，2018，118（8）：1056-1061. [21] 蒋倩，李幼平，喻佳洁，等. 全球药物价值评价工具的循
[13] PABINGER I，VAN ES N，HEINZE G，et al. A clinical 证评价[J]. 中国循证医学杂志，2019，19（7）：856-862.
prediction model for cancer-associated venous thromboem- JIANG Q，LI Y P，YU J J，et al. Evidence-based evalua‐
bolism：a development and validation study in two inde‐ tion of global value assessment tools[J]. Chin J Evid
pendent prospective cohorts[J]. Lancet Haematol，2018，5 Based Med，2019，19（7）：856-862.
（7）：e289-e298. （收稿日期：2023-06-28 修回日期：2023-12-12）
[14] ROJAS-HERNANDEZ C M，TANG V K，SANCHEZ- （编辑：刘明伟）

· 338 · China Pharmacy 2024 Vol. 35 No. 3 中国药房 2024年第35卷第3期